RECORDATI ORD overview

RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA ® IN EUROPE Vazkepa ® supported by strong clinical data package and expected to contribute to Specialty & Primary Care growth in coming years Milan, 24 June 2025 – Recordati today announced a licensing and supply agreement with Amarin to commercialize the marketed cardiovascular medicine, Vazkepa ® (icosapent ethyl) across 59 countries, focused in Europe. Vazkepa ® is indicated to reduce the...

RECORDATI: TO BE HIGHLIGHTED AT AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGY (AACE) ANNUAL MEETING--THE EXPANDED INDICATION FOR ISTURISA® (OSILODROSTAT) FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN ADULT PATIENTS WITH CUSHING'S SYNDROME FOR WHOM SURGERY IS NOT AN OPTION OR HAS NOT BEEN CURATIVE PR Newswire MILAN and BRIDGEWATER, N.J., May 15, 2025 ISTURISA ® (osilodrostat) is a cortisol synthesis inhibitor that blocks the enzyme 11beta-hydroxylase to help normalize hypercortisolemia...

Consolidated net revenue of € 680.0 million in the first quarter of 2025, +11.9% or +7.2% on a like-for-like basis (3) and at constant exchange rates (CER) EBITDA (1) of € 270.2 million, +10.7%, margin on revenue of 39.7% Adjusted net income (2) of € 175.5 million, +7.2% Net income of € 125.0 million, +1.2% Free cash flow (4) of € 158.8 million, +€ 11.7 million vs prior year Net debt (5) at € 2,020.8 million, just below 2.2x EBITDA pro-forma (6) Isturisa ® granted expanded...

RECORDATI: 2025-2027 THREE-YEAR PLAN APPROVED FY 2027 TARGETS OF REVENUE BETWEEN € 3,000 AND € 3,200 MILLION; EBITDA (1) BETWEEN € 1,140 AND € 1,225 MILLION; ADJUSTED NET INCOME (2) BETWEEN € 770 AND € 820 MILLION Milan, 28 th April 2025 – The Board of Directors of Recordati S.p.A. has reviewed and approved the plan for the 2025-2027 three-year period. Recordati will continue executing on its strategy focused on driving organic growth of its current product portfolio across both...

RECORDATI: FDA GRANTS ISTURISA ® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME ISTURISA ® is a cortisol synthesis inhibitor that blocks the enzyme 11β-hydroxylase to help normalize hypercortisolemia in Cushing’s syndrome, a rare endocrine condition that can have significant impact on patients and their families The expanded indication is supported by an extensive clinical development program Milan, Italy and...

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA ( 1) +12.5%, ADJUSTED NET INCOME (2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS Consolidated net revenue of € 2,341.6 million for FY 2024, +12.4% or +9.2% on a like-for-like basis ( 3) and at constant exchange rates (CER) EBITDA ( 1) of € 865.8 million, +12.5%, revenue margin of 37.0% Adjusted net income ( 2) of € 568.9 million, +8.4% Net income of € 416.5 million, +7.0% Free cash flow ( 4)...

Consolidated net revenue of € 1,743.1 million in the first nine months, +12.0% or +9.3% on a like-for-like basis (3) and at constant exchange rates (CER) EBITDA (1) of € 665.7 million, +11.8%, revenue margin of 38.2% Adjusted net income (2) of € 445.4 million, +9.5% Net income of € 338.4 million, +11.1% Free cash flow (4) at € 434.3 million, +€ 42.5 million vs prior year Net debt (5) at € 1,317.3 million, just below 1.6x EBITDA Financial targets for FY 2024 confirmed, excluding any...